
MNKD AI Price Prediction
Track MNKD's AI-powered predictions, market trends, and investment insights.
You don't hold MNKD in your mock portfolio yet.
Track MNKD's AI-powered predictions, market trends, and investment insights.
You don't hold MNKD in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedMannKind remains unprofitable, as indicated by its negative EPS of -0.07 and a correspondingly negative P/E ratio of -53.86. This suggests that, despite any recent operational progress, the company is still in a loss-making phase and investors are paying a relatively high price for negative earnings. Without evidence of a clear path to sustained profitability, the fundamental earnings profile is a headwind for the stock.
The stock’s 34.2% gain over the last month signals strong short-term momentum, but the current price of $3.77 remains below the 200-day moving average of $4.57. Trading below the long-term moving average typically indicates the longer-term trend is still weak or in recovery. Without additional confirmation (e.g., a move back above the 200-day average or supportive volume/RSI data), the technical picture is cautiously neutral.
Alternative data points show signs of underlying operational and brand momentum. Job openings have risen 37% month over month, which often signals growth initiatives, investment in capacity, or pipeline execution. Social media and LinkedIn followings are growing steadily, indicating gradually increasing awareness and engagement around the company.
MannKind shows improving short-term stock momentum and constructive alternative data signals, but its negative earnings profile and price still below the 200-day moving average temper the outlook. The stock appears to be in a recovery phase where sentiment and growth expectations are important, yet not fully supported by profitability. Overall, the balance of signals is neutral, with upside potential contingent on execution toward sustainable earnings.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
MannKind Corporation (NASDAQ: MNKD) is trading at $3.77, posting a notable single-day gain of 3.6% on elevated volume of nearly 19.9 million shares — well above typical activity for a $1.2 billion market cap biopharmaceutical company. The spike suggests short-term momentum or event-driven interest, potentially tied to news around its inhaled insulin product Afrezza, its collaboration with United Therapeutics, or broader biotech sector moves. With 37 active job postings, the company shows signs of operational activity, though the hiring footprint remains modest relative to its pipeline ambitions.
TrendEdge's AI model assigns MNKD a score of 4 out of 10, reflecting a cautious outlook despite today's price pop. A below-midpoint score typically indicates that while some short-term signals are positive — such as the day's volume surge — the broader data composite does not support a sustained bullish trend. Factors likely weighing on the score include the stock's low absolute price point, limited social sentiment data, and the inherent commercialization risks facing a specialty biopharmaceutical company with a niche inhaled-insulin product. The score suggests the current move warrants scrutiny rather than conviction.
Key catalysts to monitor for MNKD in 2026 include progress under its United Therapeutics collaboration, uptake data for Afrezza and Thyquidity, and any updates from its NRx Pharmaceuticals dry powder formulation agreement. Risks include continued revenue concentration in a competitive diabetes market, cash burn typical of commercial-stage biopharma, and limited retail sentiment visibility. The 4/10 AI score advises watching for confirming signals before treating today's 3.6% gain as a trend reversal.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
11,572
Twitter Followers
2,787
Instagram Followers
1,369
YouTube Subscribers
276
LinkedIn Followers
20,638
Job Postings
37
LinkedIn Employees
833
News Mentions
1
Key Metrics